Highlights for March 2016:
- Sun Pharma acquires 14 established prescription brands from Novartis for USD 293 million
- Strides acquire Jointflex, Fergon and Vanquish brands from Moberg Pharma for USD 10 Mn
- Cipla invests further USD 3 million in Chase Pharmaceuticals
- Zydus acquires the gastro therapy 'Actibile' from Albert David Limited (ADL)
- Dr Reddy’s and XenoPort enters US licensing agreement for development and commercialization of a clinical-stage oral new chemical entity for treatment of moderate-to-severe chronic plaque psoriasis and for relapsing forms of multiple sclerosis (MS)
- Dr Reddy’s and TR-Pharm announce collaboration agreement for manufacture and commercialization of a portfolio of biosimilar drugs in Turkey
- Biocon inks co-development & commercialization agreement with Lab PiSA for rh- Insulin in USA
- Dr Reddy's entered into a licensing pact with Japan's Eisai Co. Ltd for the development and commercialization of latter's investigational anticancer agent E7777
- Lupin completes its acquisition of GAVIS
- Akumentis Healthcare is in advanced talks to acquire two firms with a focus on women's healthcare
- Trivitron Healthcare is scouting for technology collaborators for its new X-ray making unit
For more such news and updates, please join our Group "Global Life Science Business in India" on LinkedIn.
Aagami Updates:
- Aagami CEO and Head-BD complete a highly successful business trip to India along with a Client CEO and VP finalizing broad and high value partnerships.